A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of DAVANAT (A Galactomannan Derivative) in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2012
At a glance
- Drugs Fluorouracil; Galactomannan C
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2011 New trial record